Sun Pharma gets U.S. FDA nod for Prevacid generic drug

MUMBAI (Reuters) - Sun Pharmaceutical Industries Ltd (NSI:SUNPHARMA.NS - News) said its unit has received U.S. Food and Drug Administration's (USFDA) final approval for the generic version of Prevacid.

The approval is for Lansoprazole Delayed-Release Capsules USP, 15 and 30 mg, which are therapeutic equivalents of Takeda Pharmaceutical Co. Ltd's capsules, the company said in a release late on Saturday.

The capsules have annual sales of $430 million in the United Sates, it said.

The capsules are used for short-term treatment for healing and symptom relief of active duodenal ulcer, it said.

(Reporting by Subhadip Sircar; Editing by Robert Birsel)